Comparable outcomes were reported following a 12-week PMR programme, conducted in a sample of 100 women with endometriosis (50 intervention, 50 control), all receiving GnRH agonist therapy, which in combination with GnRH agonist treatment showed a significant reduction in pain, anxiety and depression (p < 0.001), as well as an increase in quality of life scores (36-Item Short Form Health Survey (SF-36): 16.64 ± 21.73 vs. 34.34 ± 18.47; p < 0.05). This evidence concerns the gene GNRH1 and depressive disorder.